Recent Updates
Recently added Catalysts
ABVX Positive Sentiment Score: 70/100

Abivax publishes financial reports with the French and U.S. securities regulatory agencies

Friday, April 5, 2024 2 min read
Key Takeaway: Abivax SA has announced the publication of its financial reports, including the Universal Registration Document with the French authorities and the 20-F Annual Report with the U.S. SEC. These filings were made on April 5, 2024, and will be available for public viewing on their website and the respective regulatory agency platforms. Additionally, a webcast is scheduled for April 8, 2024, where company management will discuss the highlights from 2023 and outline future projects.

Market Sentiment Analysis

POSITIVE FACTORS

  • Abivax has successfully filed its financial reports with regulatory agencies.
  • The publication of reports indicates transparency and compliance with regulations.
  • A webcast will provide insights into 2023 financial results and future projects.

Full Press Release Details

Abivax publishes financial reports with the French and U.S. securities regulatory agencies
PARIS, France, April 5, 2024, 10:00 p.m. CEST – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announces the filing of its Universal Registration Document (Document d’Enregistrement Universel) with the French Financial Market Authorities, Autorité des Marchés Financiers (AMF), and the filing of its Annual Report (20-F) with the U.S. Securities and Exchange Commission (SEC) on April 5, 2024.
The Universal Registration Document includes the 2023 annual financial report, the management report including the report on corporate governance, as well as the reports of the statutory auditors.
The documents will be available for download on the website of Abivax (www.abivax.com/investors), the AMF (www.amf-france.org), and the SEC (www.sec.gov/edgar).
Webcast on 2023 financial results
A webcast will be organized on Monday, April 8, 2024, at 2:30 p.m. CEST (8:30 a.m. EST) following the announcement of the 2023 yearly results. The Abivax management will give an overview of the Company’s 2023 highlights and projects going forward, followed by a live Q&A session.
To participate and ask questions during the webcast, please register via the Abivax website.
Abivax Investor Relations
patrick.malloy@abivax.com

Tags

Financial report (20-F)

Frequently Asked Questions

When did Abivax publish its financial reports?

Abivax published its financial reports on April 5, 2024.

Where can I find Abivax's financial documents?

Financial documents are available on Abivax's website and regulatory agency sites.

What is included in the Universal Registration Document?

It includes the 2023 annual financial report and corporate governance information.

When is the webcast for Abivax's financial results?

The webcast will be held on April 8, 2024, at 2:30 p.m. CEST.

How can I participate in the webcast?

You can register to participate on the Abivax website.

Tags: ABVX Viatris Investor Conferences Healthcare Abivax financial reports securities regulation 20-F filing Universal Registration Document
Last updated: Apr 5, 2024